US$24.13m cholera vaccine plant construction starts
US$24.13m cholera vaccine plant construction starts
Content Type: Free
By BARNABAS ZULU
GOVERNMENT has commenced the construction of a cholera vaccine manufacturing facility in Zambia at a cost of US$24.13 million for the first phase of the project.
The facility, which will be known as ZAMVAX Limited, is being established through a partnership between the Industrial Development Corporation (IDC) and China's Jijia International Medical Technology Company Limited.
Speaking during the groundbreaking ceremony in Lusaka yesterday, Health Minister Professor Roma Chilengi said the project was an important step towards achieving public health security and vaccine independence.
Prof Chilengi said the Covid-19 pandemic had exposed the challenges African countries faced when depending on other nations for essential medical supplies, including vaccines.
“Coming from the famous Covid-19 experience, it was clear that much of Africa and the global community that commodity sovereignty is not an option if you want to achieve public health security,” Prof Chilengi said.
He said Zambia continued to lose lives to cholera despite the availability of vaccines, making local manufacturing an important intervention in addressing the disease.
“As a professor of vaccinology myself, I can tell you that nothing pleases me more than to see work in the vaccine space that gets us to a place where we can manufacture vaccines in Zambia,” Prof Chilengi said.
And IDC chief executive officer Cornwell Muleya said the corporation's ambition was to end the country's reliance on foreign suppliers during health emergencies.
“Our ambition is to make Zambia fully self-sufficient in meeting its cholera vaccine needs, while building the capability to supply a broader range of vaccines for our children and our region,” Mr Muleya said.
Mr Muleya said although the initial phase would focus on oral cholera vaccines, the facility was eventually expected to expand production to include childhood and animal vaccines, as well as other vaccines required under the country's expanded immunisation programme.
He said the expansion would strengthen vaccine availability and build the country's capacity to serve both domestic and regional markets.
The first phase will involve filling, finishing, packaging and quality control of oral cholera vaccines using imported bulk vaccine ingredients, with a planned production capacity of up to 20 million doses annually.
The second phase is expected to introduce local production of vaccine antigens, paving the way for full-scale local manufacturing.
IDC holds a 60 percent stake in ZAMVAX, while Jijia holds the remaining 40 percent.
Ends.

Nation Reporter
